Skip to main content

Meet with our product experts in one-on-one virtual sessions

Set Up a Meeting
Quick Connect


Lurbinectedin API


CAS Number: 497871-47-3

Therapeutic Category
Anti-Cancer/ Oncology
API Technology
Dose Form
Dr Reddy's Development Status
Innovator Brand (USA)

Mechanism of Action

Lurbinectedin is an antineoplastic agent that belongs to the class of drugs called alkylating agents. It works by inducing DNA damage and blocking DNA repair, leading to cell death in cancer cells.

The mechanism of action of lurbinectedin involves the binding of the drug to DNA and the formation of covalent bonds with the DNA molecule. This binding leads to the formation of DNA adducts, which interfere with the normal functioning of DNA, including DNA replication and transcription.

Lurbinectedin specifically targets a type of RNA transcription called ""RNA polymerase II termination factor (RTF)"" which is overproduced in certain cancer cells. By inhibiting RTF, lurbinectedin causes the accumulation of RNA polymerase II on the DNA, leading to DNA damage and the eventual death of the cancer cell.


Lurbinectedin is a chemotherapy drug that is indicated for the treatment of advanced small cell lung cancer (SCLC) in adult patients with disease progression on or after platinum-based chemotherapy. It is also indicated for the treatment of adult patients with relapsed and refractory small cell lung cancer (RR-SCLC) who have received at least two prior lines of therapy.

It works by binding to and inhibiting the activity of an enzyme called RNA polymerase, which is important for the replication of cancer cells. This leads to the death of cancer cells and slows the progression of the disease.

Lurbinectedin should be administered under the supervision of a qualified healthcare provider experienced in the administration of cancer chemotherapy. It is important to carefully follow the dosing and administration instructions provided by your healthcare provider.

Dr. Reddy's Expertise

Headquartered in Hyderabad, India, Dr. Reddy's Laboratories is one of the leading Active Pharmaceutical Ingredients (API) manufacturers and suppliers globally for Lurbinectedin API. Dr. Reddy's API business is a preferred partner to pharma companies across the US, Europe, Brazil, Latin America, Japan, China, Korea, Middle East and other emerging markets.

Dr. Reddy's API business thrives on the deep technical strengths established over the last 30+ years in the development and manufacture of complex APIs such as steroids, peptides, complex long chain molecules and highly potent APIs (HPAPIs / oncology drugs). This expertise is complemented by our prowess in intellectual property and regulatory affairs which helps us consistently meet and exceed regulatory standards. Dr. Reddy's Lurbinectedin API is the outcome of the extensive expertise in R&D, IP, and Regulatory.

A key component in helping our customers be first to market is a responsive supply chain. We achieve this by making sure that all our facilities are operating efficiently and to the latest standards of quality, safety, and productivity. A strong interconnect between business and factories allows for a quick reaction to dynamic market changes, so that we can avert shortages and meet sudden surges in demand.

Oncology API Products:

Learn More

Contact Us

Please fill in the following form for API Requirement & we'll get back to you shortly

We are here to help, if you have any country specific requirements.


No information in this catalog - including any reference to any product or service - constitutes an offer for sale, or be construed as representing an offer for sale. Products protected under valid patents are not offered or supplied for commercial use. However, the research quantities of such products may be offered for the purpose of regulatory submissions, wherever such regulatory exemptions exist. The buyers should make their independent evaluation of the patent scenario for their respective markets and will be responsible for all patent related liabilities. Products protected under valid patents in India are not available for commercial use but would be available for Section 107A purposes.